NBIX · CIK 914475
What Neurocrine Biosciences, Inc. told the SEC could break it.
Neurocrine is concentrated at both ends of its INGREZZA and CRENESSITY business. It sells through a limited specialty network, where one customer was 39% of total gross product revenue in 2025 (and 41% of accounts receivable), concentrating distribution and credit exposure. On supply, it depends on a limited number of third parties for production — including API — and packaging, with manufacturing in Europe and some China-based collaborators, so a supplier's manufacturing, quality or compliance failure could materially hurt its ability to develop and commercialize. That overseas-made supply chain is also exposed to pharmaceutical tariffs: an April 2025 U.S. Commerce investigation into pharmaceutical imports, plus a signaled possible 100% tariff on branded or patented drugs unless a company builds U.S. manufacturing.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- specialty-pharmacy distributor (Customer A, 39% of gross product revenues)high
Neurocrine sells INGREZZA/CRENESSITY through a limited specialty network; one customer ('Customer A') was 39% of total gross product revenues in 2025 (43%/36% in 2024/2023) and 41% of accounts receivable, concentrating distribution and credit exposure.
“The following table presents the percent of total gross product sales and total accounts receivable for each of our customers who individually accounted for 10% or more of total gross product sales and/or 10% or more of total accounts receivable. Percent of Percent of Total Gross Product Revenues Accounts Receivable Year Ended December 31, December 31, 2025 2024 2023 2025 2024 Customer A 39 % 43 % 36 % 41 % 41”
SEC filing →As of 2026
Supplier concentration
- limited-number API/production/packaging suppliershigh
Neurocrine depends on a limited number of third-party suppliers for the production (including API) and packaging of INGREZZA, CRENESSITY and its candidates (with some collaborators in China and manufacturing in Europe); supplier manufacturing/quality/compliance problems could materially harm development and commercialization.
“We depend on a limited number of suppliers for the production (including API) of INGREZZA, CRENESSITY, and our product candidates and for the packaging of INGREZZA and CRENESSITY. If our third-party suppliers for INGREZZA, CRENESSITY, or any of our product candidates encounter these or any other manufacturing, quality, or compliance difficulties, our ability to successfully develop or commercialize INGREZZA, CRENESSITY, or any of our product candidates could be materially and adversely affected.”
SEC filing →As of 2026
Regulatory & policy
- pharmaceutical import tariffsmedium
An April 2025 US Commerce Department Section 232-style investigation into pharmaceutical imports could lead to industry tariffs, and the administration has signaled a possible 100% tariff on branded/patented pharmaceuticals (unless building US manufacturing) — relevant to Neurocrine, whose products are made by third parties in Europe with some China-based suppliers.
“In April 2025, the U.S. Department of Commerce initiated an investigation on imports of pharmaceuticals and pharmaceutical ingredients, which may result in the current U.S. presidential administration taking actions to impose tariffs on the pharmaceutical industry. The U.S. presidential administration also indicated that it may impose a 100% tariff on any branded or patented pharmaceutical product, unless a company is building a pharmaceutical manufacturing plant in the U.S.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“AbbVie retains global commercialization rights to elagolix.”
Cited →Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma)
“INGREZZA is marketed as DYSVAL ® (valbenazine) in Japan and REMLEAS ® (valbenazine) in other select Asian markets, where Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) retains commercialization rights.”
Cited →
Its suppliers
“Except for the activities set forth in the development plans, Neurocrine Biosciences is solely responsible, at its sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to the Co-Funding Option”
Cited →“For the year ended December 31, 2025, we recognized $30.5 million of collaboration revenue from the 2023 Neurocrine Collaboration Agreement, $5.9 million of collaboration revenue from the 2023 Novartis Collaboration Agreement, $3.5 million of collaboration revenue from the 2019 Neurocrine Collaboration Agreement, and $0.5 million of collaboration revenue from other agreements.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch